Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

Concept,Of,Huntington's,Disease,Write,On,Sticky,Notes,With,Stethoscope

uniQure N.V. (NASDAQ:QURE) on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s disease.

Huntington’s disease is an inherited condition in which nerve cells in the brain break down over time. The disease affects a person’s movements, thinking ability and mental health.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.